CV Sciences Cuts Costs 17.2%, Lifts Gross Margin to 49% for FY 2025
CV Sciences reported fiscal 2025 revenue of $13.8 million, down from $15.7 million, while gross margin improved to 49.0% from 45.6%. The company cut operating expenses 17.2% to $7.7 million, reduced adjusted EBITDA loss to $0.3 million, swung Q4 adjusted EBITDA to $0.1 million and held $0.3 million cash.
1. Fiscal 2025 Revenue and Margins
In fiscal 2025, CV Sciences generated $13.8 million in revenue, down from $15.7 million the prior year. Gross margin improved to 49.0% from 45.6%, while Q4 margin reached 50.5% compared to 43.2% a year earlier.
2. Cost Reductions and EBITDA Performance
The company reduced operating expenses by 17.2% to $7.7 million, excluding payroll tax reversals, leading to a narrowed adjusted EBITDA loss of $0.3 million for the year and a positive $0.1 million in Q4.
3. Product Launches and Financial Position
CV Sciences launched the Ignite men's performance formula in Q3 2025 and the EMPOWR plant-based protein in Q1 2026. A debt restructuring in Q1 2026 strengthened liquidity, though year-end cash stood at $0.3 million.